Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Dermatologic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1228Lung Neoplasms 560Colorectal Neoplasms 282Breast Neoplasms 257Neoplasms 254Melanoma 236Small Cell Lung Carcinoma 234Ovarian Neoplasms 234Pancreatic Neoplasms 186Squamous Cell Carcinoma of Head and Neck 171Neoplasm Metastasis 171Carcinoma, Renal Cell 164Stomach Neoplasms 158Triple Negative Breast Neoplasms 127Head and Neck Neoplasms 121Esophageal Neoplasms 115Prostatic Neoplasms 106Urinary Bladder Neoplasms 105Colonic Neoplasms 95Uterine Cervical Neoplasms 93Endometrial Neoplasms 93Mesothelioma 84Mesothelioma, Malignant 79Carcinoma, Hepatocellular 78Sarcoma 70Carcinoma, Transitional Cell 69Kidney Neoplasms 65Carcinoma, Ovarian Epithelial 50Adenocarcinoma of Lung 47Rectal Neoplasms 45

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Melanoma, Cutaneous Malignant × Thoracic × Clear all
NCT05479812 2026-02-09

Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors

Werewolf Therapeutics, Inc.

Phase 1 Active not recruiting
150 enrolled
DermatologicGenitourinaryThoracic

Melanoma, Cutaneous Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡